# US 4,400,375 A · Tobramycin-double stranded RNA complex suitable for inducing interferon

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,400,375 A
- Document ID: US4400375A
- Status: Granted
- Kind: A
- Application number: 06/324,241
- Filed: 1981-11-23
- Granted: 1983-08-23
- Earliest claimed: 1981-11-23
- Assignees: Eli Lilly and Company
- Inventors: Richard J. Douthart; Walter J. Kleinschmidt; Richard M. Schultz
- Web page: https://patentgrep.com/patent/US4400375A

## CPC

- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61P 35/00: Antineoplastic agents
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

A complex is described which is useful in inducing interferon production, in activating peritoneal macrophages, and in inhibiting the proliferation and migration of tumor cells, which complex comprises natural or synthetic double stranded RNA and tobramycin.

## Claims

### Claim 1

A complex comprising (a) natural or synthetic double stranded RNA and (b) tobramycin in a molar ratio of tobramycin to double stranded RNA phosphorus of at least about 1:1.

### Claim 2 (depends on 1)

Complex of claim 1, in which the double stranded RNA is of natural origin.

### Claim 3 (depends on 2)

Complex of claim 2, in which the double stranded RNA source is Penicillium chrysogenum.

### Claim 4 (depends on 3)

Complex of claim 3, in which the molar ratio of tobramycin to double stranded RNA phosphorus is from about 12:1 to about 1:1.

### Claim 5 (depends on 3)

Complex of claim 3, in which the molar ratio of tobramycin to double stranded RNA phosphorus is from about 9:1 to about 6:1.

### Claim 6

A pharmaceutical composition suitable for inducing interferon comprising in combination with a pharmaceutically acceptable carrier an interferon-inducing amount of a complex of (a) natural or synthetic double stranded RNA and (b) tobramycin in a molar ratio of tobramycin to double stranded RNA phosphorus of at least about 1:1.

### Claim 7 (depends on 6)

Composition of claim 6, in which the double stranded RNA is of natural origin.

### Claim 8 (depends on 7)

Composition of claim 7, in which the double stranded RNA source is Penicillium chrysogenum.

### Claim 9 (depends on 8)

Composition of claim 8, in which the molar ratio of tobramycin to double stranded RNA phosphorus is from about 12:1 to about 1:1.

### Claim 10 (depends on 8)

Composition of claim 8, in which the molar ratio of tobramycin to double stranded RNA phosphorus is from about 9:1 to about 6:1.